AR106198A1 - BISPECIFIC ANTIBODIES FOR THE PROGRAMMED CELL DEATH PROTEIN 1 (PD1) AND FOR THE HUMAN PROTEIN BELONGING TO THE IMMUNOGLOBULIN SUPERFAMILY (TIM3) - Google Patents

BISPECIFIC ANTIBODIES FOR THE PROGRAMMED CELL DEATH PROTEIN 1 (PD1) AND FOR THE HUMAN PROTEIN BELONGING TO THE IMMUNOGLOBULIN SUPERFAMILY (TIM3)

Info

Publication number
AR106198A1
AR106198A1 ARP160102983A ARP160102983A AR106198A1 AR 106198 A1 AR106198 A1 AR 106198A1 AR P160102983 A ARP160102983 A AR P160102983A AR P160102983 A ARP160102983 A AR P160102983A AR 106198 A1 AR106198 A1 AR 106198A1
Authority
AR
Argentina
Prior art keywords
tim3
bispecific antibodies
cell death
programmed cell
immunoglobulin superfamily
Prior art date
Application number
ARP160102983A
Other languages
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR106198A1 publication Critical patent/AR106198A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La divulgación se refiere a anticuerpos biespecíficos que comprenden un primer sitio de unión a antígeno que se une específicamente a PD1 y un segundo sitio de unión a antígeno que se une específicamente a TIM3, en particular a anticuerpos biespecíficos, en el que el anticuerpo biespecífico se une a TIM3 con una afinidad menor en comparación con la unión a PD1. La divulgación se refiere además a métodos para producir estas moléculas y a métodos para usar las mismas, en prevención o tratamiento del cáncer.The disclosure relates to bispecific antibodies comprising a first antigen binding site that specifically binds PD1 and a second antigen binding site that specifically binds TIM3, in particular bispecific antibodies, in which the bispecific antibody is binds TIM3 with a lower affinity compared to PD1 binding. The disclosure also refers to methods for producing these molecules and methods for using them, in cancer prevention or treatment.

ARP160102983A 2015-10-02 2016-09-29 BISPECIFIC ANTIBODIES FOR THE PROGRAMMED CELL DEATH PROTEIN 1 (PD1) AND FOR THE HUMAN PROTEIN BELONGING TO THE IMMUNOGLOBULIN SUPERFAMILY (TIM3) AR106198A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15188036 2015-10-02

Publications (1)

Publication Number Publication Date
AR106198A1 true AR106198A1 (en) 2017-12-20

Family

ID=54256606

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102983A AR106198A1 (en) 2015-10-02 2016-09-29 BISPECIFIC ANTIBODIES FOR THE PROGRAMMED CELL DEATH PROTEIN 1 (PD1) AND FOR THE HUMAN PROTEIN BELONGING TO THE IMMUNOGLOBULIN SUPERFAMILY (TIM3)

Country Status (1)

Country Link
AR (1) AR106198A1 (en)

Similar Documents

Publication Publication Date Title
CL2018000502A1 (en) Bispecific antibodies for pd1 and tim3 useful as immunomodulators or in the treatment of cancer.
CL2019001926A1 (en) Anti-tigit antibodies and antigen-binding fragments; pharmaceutical composition comprising them; polynenucleotide encoding said antibody; vector comprising them, host cell; method of producing said antibody or antigen-binding fragment thereof; and use in the treatment of cancer. (Divisional Application 310-2017).
ECSP19078429A (en) ANTI-TREM2 ANTIBODIES AND METHODS TO USE THEM
EA202090812A1 (en) NEW BISPECIFIC POLYPEPTIDE COMPLEXES
CO2018012415A2 (en) Specific binding proteins and uses thereof
EA201791666A1 (en) CD3 ANTIBODIES, CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES THAT SPECIFICALLY CONNECT WITH CD3 AND / OR CD123
CL2018001326A1 (en) Ctla4 binding proteins.
PE20240111A1 (en) BINDING MOLECULES TO PD-1 AND METHODS OF USE THEREOF
MY200602A (en) Antibodies against tim3 and uses thereof
EA201792221A1 (en) ANTIBODIES AGAINST SORTILINE AND METHODS OF THEIR APPLICATION
BR112017025191A2 (en) ox40 antibodies and their use
UY36859A (en) ANTI-BCMA ANTIBODIES, MOLECULES OF UNION TO BIESPECTIFIC ANTIGENS THAT JOIN BCMA AND CD3, AND USES OF THESE
CR20180065A (en) BIESPECTIFIC ANTIBODY CONSTRUCTS THAT JOIN EGFRVIII AND CD3
AR107442A1 (en) ANTIBODIES AGAINST THE ORPHANE RECEPTOR SIMILAR TO THE THIROSINE QUINASE 1 (ANTI-ROR1) RECEPTOR, BISPECIFIC ANTIBODIES THAT JOIN ROR1 AND THE CD3 ANTIGEN, AND METHODS FOR TREATMENT OF CANCER
PE20171180A1 (en) ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE
PE20171654A1 (en) COMPOSITIONS AND METHODS USED TO INCREASE IMMUNE RESPONSE AND IN CANCER THERAPY
PE20180499A1 (en) UNION TO TAU ANTIBODIES
PE20190737A1 (en) ANTI-CD27 ANTIBODIES
EA201692504A1 (en) TRISPECIFIC BINDING MOLECULES AND METHODS OF THEIR APPLICATION
BR112019024654A2 (en) binding protein nkg2d, cd16 and ror1 or ror2
ECSP19078414A (en) ANTI-CD33 ANTIBODIES AND METHODS TO USE THEM
MX2022006461A (en) Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof.
CO2018003852A2 (en) Antigen binding proteins that activate the leptin receptor
EA201491599A1 (en) ANTIBODIES TO MATRIX METALLOPROTEINASE 9
MX2022009915A (en) Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof.